Eisai Co., Ltd., et al. v. Glenmark Pharmaceuticals, Ltd., et al., C.A. No. 13 – 1279 – LPS, March 17, 2015.
Stark, C. J. The court issues claim constructions regarding 7 terms from 3 patents.
The following terms were construed:
-
“crystal modification A”
-
“characterized by characteristic lines at [with] interplanar spacings (d values) of 10.5 Å, 5.14 Å, 4.84 Å, 4.55 Å, 4.34 A, 4.07 Å, 3.51 Å,3.48 Å, 3.25 Å, 3.19 Å, 3.15 Å, 3.07 Å, 2.81 Å, [as] determined by means of an X-ray powder pattern”
-
A. “characterized by the following absorptions in the FT-IR spectrum (KBr pellet-transmission method) at 3092 cm-1 and 3412 cm-1”
B. “characterized by bands at 3412 cm-1 and3092 cm-1 in the FT-IR spectrum”
C. “characterized by absorption bands at 3412 cm-1 and 3092 cm-1 in the FT-IR spectrum (KBr pellet-transmission method)”
-
A. “characterized by bands at 1080 cm-1 in the FT-[Raman] spectrum”
B. “characterized by an absorption band at 1080 cm-1 in the FT-Raman spectrum”
-
“characterized by an endothermic peak in the range from 230° C. to 260° , the peak temperature being 239-245° C., and the endothermic signal being 209 J/g+/-10 J/g”
-
“sodium carboxymethylcellulose”
-
“in essentially pure form”
